Preliminary results of rituximab in progressive MS


REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page